Research programme: Alzheimer's disease therapy - Satori Pharmaceuticals

Drug Profile

Research programme: Alzheimer's disease therapy - Satori Pharmaceuticals

Alternative Names: Alzheimer's disease therapy research programme - Satori Pharmaceuticals; SPI 1865; SPI-014

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Satori Pharmaceuticals
  • Class
  • Mechanism of Action Amyloid precursor protein secretase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 11 Jul 2012 Preclinical development is ongoing in USA
  • 20 Jul 2011 This programme is in active development
  • 20 Sep 2005 Preclinical trials in Alzheimer's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top